Introduction
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial or venous thrombosis and pregnancy complications, including recurrent spontaneous abortion.
1,2 APS is associated with antiphospholipid (aPL) antibodies that bind to anionic phospholipid and serum protein complexes. [3] [4] [5] Interactions between aPL antibodies and vascular endothelial cells are thought to be involved in the pathogenesis of APS.
6-9 β 2GPI is the main phospholipid-binding molecule recognized by aPL antibodies 5, 10, 11 and is produced predominantly by hepatocytes, although some endothelial cells of blood vessels and placental villous tissue also express it.
12,13
Plasma β2GPI circulates in a circular conformation with the aPL antibody epitopes being cryptic.
14 When β2GPI associates with anionic phospholipids such as cardiolipin (CL), the circular structure of plasma β2GPI is converted to a linear form, leading to exposure of the major epitope for aPL antibodies. 14-19 Therefore, β2GPI bound to negatively charged phospholipids or negatively charged plates is clinically used to detect antibodies. 20 However, autoantibodies against the β2GPI associated with phospholipids are detected in less than half of patients with clinical manifestations of APS, [21] [22] [23] suggesting the existence of additional targets of the autoantibodies. In addition, β2GPI is a secreted protein and is generally not present on the cell surface; therefore, how aPL antibodies bind vascular endothelial cells and induce thrombosis or pregnancy complications has remained unclear.
Specific HLA class II alleles are associated with susceptibility to APS, similar to other autoimmune diseases. [24] [25] [26] [27] Because peptide repertoires presented on different HLA class II alleles differ, 28, 29 it has been proposed that specific peptide-HLA class II combinations affect T cell development and/or tolerance, which may confer susceptibility or resistance to autoimmune diseases. 30 Nonetheless, the mechanisms by which HLA class II gene polymorphisms regulate susceptibility to autoimmune diseases are unknown.
Misfolded cellular proteins are generally eliminated by the process of endoplasmic reticulum-associated degradation (ERAD) 31 and would not be exposed to the immune system.
Recently, however, we found that misfolded proteins are rescued from degradation and transported to the cell surface without processing to peptides when they associate with the peptide-binding groove of HLA class II molecules in the endoplasmic reticulum (ER). 32, 33 Structural analyses of MHC class II molecules have revealed that both ends of the MHC class II Furthermore, IgG heavy chains thus transported to the cell surface by alleles of HLA class II associated with rheumatoid arthritis (RA) susceptibility were specifically recognized by autoantibodies from RA patients. 33 Because HLA class II expression on non-lymphoid cells, including endothelial cells, is frequently observed in various autoimmune diseased tissues, [37] [38] [39] [40] [41] we hypothesized that misfolded proteins rescued from protein degradation by HLA class II molecules might be targets for autoantibodies in autoimmune diseases. Here, we addressed whether structurally altered β2GPI is transported to the cell surface by HLA class II molecules and is recognized by autoantibodies in APS patients. Strikingly, 100 of the 120 of APS patients (83.3%), including those whose aPL antibody titers were within normal range, possessed autoantibodies against β2GPI/HLA class II complexes. Furthermore, autoantibodies from APS patients mediated complement-dependent cytotoxicity against cells expressing both β2GPI and HLA class II molecules. Our findings provide new insights not only into the Tanimura et al. Page 6 pathogenesis of APS but also an unexpected function of HLA class II molecules in autoimmune diseases.
Materials and methods

Sera and placental tissue samples
The collection and use of human sera and placental tissues was approved by the institutional 
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously. 46 Briefly, cells were lysed in buffer containing 0.5% NP-40. The immunoprecipitates were separated by SDS-PAGE, and were blotted. Total cell lysates were also analyzed by immunoblotting.
Immunohistochemistry and in situ proximity-ligation assay (PLA)
Paraffin-embedded tissue sections from APS patients (n=6) and individuals without APS (n=6)
were stained with anti-β2GPI and anti-HLA-DR Abs, followed by Alexa 647-or Alexa 555-conjugated goat anti-rabbit IgG or mouse IgG Ab (Molecular Probes). A Duolink was used for PLA according to the manufacturer's instructions (Olink Bioscience). The assayed tissue sections were analyzed by Axioplan 2 fluorescence microscopy (Zeiss). 
Effect of exogenous
Statistics
To assess the significance of the correlation, Pearson's product-moment correlation coefficient was used and the correlation coefficient (r) and P value of the linear regression line were calculated. Student's t-test and Mann-Whitney U test were used to determine significance of differences. P values of <0.05 were regarded as statistically significant.
Results
β2GPI complexed with HLA class II molecules is recognized by aPL antibody
Free β2GPI has a circular conformation whereas phospholipid-bound β2GPI has a linear conformation that is accessible by aPL antibodies ( Figure 1A ). (HLA-DR8), and cell surface expression of β2GPI on GFP-positive cells was analyzed.
was not detected on the surface of cells transfected with β2GPI alone ( Figure 1B ). In contrast, it was found on the surface of cells co-transfected with HLA-DR7, an APS-susceptibility allele. [24] [25] [26] [27] Cells co-transfected with HLA-DR8, an allele not associated with APS susceptibility, expressed less surface β2GPI ( Figure 1B ). Similar results were obtained using N-terminus Flag-tagged β2GPI or C-terminus His-tagged β2GPI detected with anti-Flag or anti-His mAb, respectively β 2GPI of the predicted size was co-precipitated together with HLA-DR7 from cells expressing both β2GPI and HLA-DR7 ( Figure 1C ). Similarly, HLA-DR was co-precipitated together with β2GPI from the transfectants. Because association of full-length IgG heavy chain with HLA-DR was detected in the ER, 33 full-length β2GPI, but not fragmented β2GPI, also seems to be associated with HLA-DR in the ER and transported to the cell surface by HLA-DR ( Figure 1A ).
APS patients possess autoantibodies that bind to cryptic epitopes on β2GPI revealed by conformational changes induced by association with phospholipids. 14-18 We tested the possibility that conformation of β2GPI bound to HLA-DR7 is similar to β2GPI complexed with phospholipids and thus is recognized by aPL antibodies from APS patients. EY2C9, a well characterized human aPL mAb derived from an APS patient, represents binding and procoagulant properties of anti-β2GPI found in APS patients. EY2C9 mAb binds to β2GPI complexed with phospholipids but neither to β2GPI nor phospholipids alone. 45 We found that EY2C9 mAb bound well to cells expressing both β2GPI and HLA-DR7, but not β2GPI alone, in the absence of phospholipids. EY2C9 mAb bound weakly to cells expressing β2GPI together with HLA-DR8 ( Figure 1B ). Because EY2C9 recognizes β2GPI associated with phosphatidylserine, we analyzed cell surface phosphatidylserine on HLA-DR7 and HLA-DR8 transfectants using annexin V, which binds to phosphatidylserine. There was no difference in annexin V binding to HLA-DR7 and HLA-DR8 transfectants, suggesting that preferential binding of EY2C9 to β2GPI and HLA-DR7 transfectants is not due to an increase of cell surface phosphatidylserine on HLA-DR7 transfectants (supplemental Figure 2 ). In addition, an HLA-Cw4 peptide (a peptide naturally bound to HLA-DR4 47 antibody, without affecting cell surface expression of HLA-DR ( Figure 1D ). These findings indicated that aPL antibody recognizes β2GPI bound to the peptide-binding groove of HLA-DR.
Furthermore, the EY2C9 mAb binding to β2GPI complexed with HLA-DR7 was blocked by β2GPI complexed with cardiolipin, but not by β2GPI alone or cardiolipin alone (Figure 2A and 2B). These data indicate that EY2C9 mAb recognizes an epitope conserved between β2GPI/HLA-DR7 complexes and β2GPI/phospholipid complexes. It has been suggested that domain I, IV, and V of β2GPI are involved in EY2C9 mAb binding.
Indeed, when domain I-deleted β2GPI and HLA-DR were cotransfected, EY2C9 mAb failed to recognize the domain I-deleted β2GPI complexed with HLA-DR7, although the mutant β2GPI complexed with HLA-DR7 was well recognized by anti-β2GPI domain IV-V Ab (supplemental Figure 3) . These data suggested that the domain I plays a critical role for EY2C9 mAb recognition of the β2GPI/HLA-DR7 complexes and that domain I is not involved in the association of β2GPI with HLA-DR7.
Autoantibodies against β2GPI complexed with HLA class II molecules are present in most APS patients
We examined whether β 2GPI complexed with HLA-DR is recognized by autoantibodies from APS patients with clinical characteristics shown in Table 1 . We found that sera from APS We analyzed whether β2GPI is complexed with HLA class II molecules on primary endothelial cells (supplemental Figure 7A ). Because it has been reported that endothelial cells express β2GPI, 12,13 and that IFN-γ and TNF-α upregulate HLA class II expression, 
Discussion
Although HLA class II molecules are well recognized to present peptide antigens to T cells, recently we found that ER misfolded proteins are transported to the cell surface by HLA class II molecules when they are associated with the peptide-binding groove of HLA class II molecules. 32 Furthermore, intact IgG heavy chain is transported to the cell surface by HLA class II molecules via association with the peptide-binding groove, and IgG heavy chain/HLA class II complexes are recognized by autoantibodies in rheumatoid factor-positive sera from RA patients 33 . In contrast, autoantibodies in rheumatoid factor-positive sera from non-RA individuals did not bind to IgG heavy chain/HLA class II complexes, suggesting that IgG heavy chain complexed with HLA-DR is a specific target for autoantibodies from RA patients. Of note, a strong correlation between autoantibody binding to IgG complexed with certain HLA-DR alleles and the odds ratio for these alleles' association with RA was observed. 33 These findings suggested that misfolded ER-proteins complexed with certain HLA class II alleles might affect susceptibility to other autoimmune diseases as a specific target for autoantibodies. On the other hand, mutational analyses of domain I suggested that domain I is also involved in EY2C9 mAb recognition of β2GPI.
0
Our analyses of domain I deletion mutants also suggest that domain I plays an important role in recognition of β2GPI/HLA-DR complexes by EY2C9 mAb. These observations support our hypothesis that pathogenic epitopes on β2GPI that are recognized by autoantibodies in APS are exposed by association with HLA-DR.
Specific HLA-DR alleles are associated with susceptibility to APS [24] [25] [26] [27] and DQB1*06:04/5/6/7/9-DRB1*13:02 haplotypes are also reported to be involved in APS susceptibility. 54 However, DRA1*01:01/DRB1*13:02 transported β2GPI to the cell surface less efficiently than HLA-DR7 and HLA-DR4. Therefore, certain HLA-DP or HLA-DQ alleles that are closely linked to the DRB1*13:02 haplotype or certain autoantigens for APS other than β2GPI, such as prothrombin, 54 might be involved in APS-susceptibility caused by the DQB1*06:04/5/6/7/9-DRB1*13:02 haplotypes.
The mechanisms of thrombosis production in patients with APS are not completely defined.
aPL antibodies are thought to induce perturbation and/or damage in endothelial cells, which results in a prothrombotic and pro-inflammatory response and subsequently thrombosis. 7, 8 It has been suggested that anti-β2GPI autoantibodies mediate NF-kB-dependent activation of endothelial cells via annexin A2 and toll-like receptor 4, which form multi-protein complexes with β2GPI. 55, 56 On the other hand, a recent study suggested that activation of platelets by aPL antibodies is associated with thrombosis formation.
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In these ways, aPL antibodies seem to be a major contributor to the pathogenesis of APS. 
